COMMUNIQUÉS West-GlobeNewswire

BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
23/09/2026
SUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided [...]
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
23/09/2026
THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company [...]
NEXGEL Announces Dial-In Details for Investor Update Call
23/09/2026
LANGHORNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a company with a patient centric medical technology sales and marketing team working closely with clinicians [...]
Cheryl Polmatier Joins U.S. Oral Surgery Management as SVP of Payer Relations
23/09/2026
IRVING, Texas, Sept. 23, 2026 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management ( USOSM ) – a management services organization that exclusively serves premier oral and maxillofacial surgeons – has named Cheryl Polmatier [...]
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
23/09/2026
- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders - REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that it has [...]
NexLife Includes a Licensed Doctor, a Nutrition Plan and Health Check-Ins After Treatment Starts in Every Compounded GLP-1 Subscription
23/09/2026
Every NexLife compounded GLP-1 subscription includes a doctor's review, a personalized nutrition plan and a 1:1 fitness coaching call alongside the medication. Ongoing care runs through Care 360, giving members 24/7 [...]
Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer
23/09/2026
Veteran biotechnology executive, Daniel Passeri brings more than three decades of experience in oncology and immunotherapy drug development - Interim CEO Dr. Bo Rode Hansen resumes role as member of the Board of [...]
ITM and Lumara Bio Announce Upcoming Dosimetry and Re-treatment Data Presentations on ¹⁷⁷Lu-edotreotide at ASTRO 2026
23/09/2026
Garching / Munich, September 23 , 2026 — ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, and Lumara Bio , a dedicated oncology therapeutics division of ITM, today announced that [...]
La rage chez les otaries à fourrure du Cap : ce que les nouvelles recherches sud-africaines pourraient signifier pour le Canada
23/09/2026
OTTAWA, Ontario, 23 sept. 2026 (GLOBE NEWSWIRE) -- L’Institut canadien de santé animale (ICSA) est fier de perpétuer sa tradition annuelle consistant à organiser un webinaire éducatif à l’occasion de la Journée mondiale [...]
Rabies in Cape Fur Seals: What New South African Research Could Mean for Canada
23/09/2026
OTTAWA, Ontario, Sept. 23, 2026 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is proud to continue its annual tradition of hosting an educational webinar in recognition of World Rabies Day. This year’s [...]
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
23/09/2026
PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its [...]
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
23/09/2026
PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ORKA-001 maintained [...]
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
23/09/2026
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will [...]
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
23/09/2026
WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
23/09/2026
In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential Sefaxersen inhibits [...]
OSE Immunotherapeutics annonce la présentation des principaux résultats de l'étude de Phase 2 Combi-TED de Tedopi® dans le cancer du poumon non à petites cellules au Congrès 2026 de l’ESMO
23/09/2026
Nantes, France, 23 septembre 2026 – 7h30 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) , une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie [...]
OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting
23/09/2026
Nantes, France, September 23, 2026 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and [...]
The Hemp Doctor's Cannabis Consumer Behavior Survey: Average Buyer Is 45
23/09/2026
A 10,214-response survey from The Hemp Doctor finds its customers are older, more self-directed, and more cannabinoid-literate than most of the industry has assumed MOORESVILLE, N.C., Sept. 23, 2026 (GLOBE NEWSWIRE) -- [...]
Anaconda Biomed Secures $56 Million Financing from New and Existing Investors
23/09/2026
Proceeds used to complete ongoing ATHENA pivotal IDE study, continue product development, and secure global regulatory approvals for neurovascular portfolio BARCELONA, Spain and MARIN, Calif., Sept. 23, 2026 (GLOBE [...]

Pages